Drugs / CD19/CD22 CAR-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04499573 | Jul 2020 → Mar 2022 overdue | — | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD22 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04499573 ↗ |
| Known as | MB-CAR-T19-22 | “automatically produced cell therapy product MB-CAR-T19-22 using CliniMACS Prodigy” NCT04499573 ↗ |
| Modality | Cell therapy | “CAR-transduced T-cell therapy” NCT04499573 ↗ |
| Route | Other | “CAR-T cells infusion” NCT04499573 ↗ |
| Target | CD19 | “CD19/CD22 CAR-T lymphocytes” NCT04499573 ↗ |
| Target | CD22 | “CD19/CD22 CAR-T lymphocytes” NCT04499573 ↗ |